The addition of IL-2 and GM-CSF to dinutuximab greatly enhanced ADCC by M1 macrophages; however, systemic IL-2 administration was found to have significant toxicity in patients, thus this treatment regimen may still need to be further optimized (104, 212), but could conceptually be applied to other pediatric solid tumors considering the GD2 is also expressed by sarcoma (213, 214). The gene discussed is IL2; the disease is sarcoma.